PACS INVESTOR DEADLINE: PACS Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

San Diego, California--(Newsfile Corp. - December 14, 2024) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of PACS Group, Inc. (NYSE: PACS): (i) securities between April 11, 2024 and November 5, 2024, all dates inclusive (the "Class Period"); and/or (ii) common stock pursuant and/or traceable to PACS Group's registration statement issued in connection with PACS Group's April 11, 2024 initial public offering ("IPO"), have until January 13, 2025 to seek appointment as lead plaintiff of the PACS Group class action lawsuit. Captioned Manchin v. PACS Group, Inc., No. 24-cv-08636 (S.D.N.Y.), the PACS Group class action lawsuit charges PACS Group as well as certain of PACS Group's top executives, directors, and certain underwriters of the IPO with violations of the Securities Act of 1933 and/or the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the PACS Group class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-pacs-group-inc-class-action-lawsuit-pacs ...

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [e-mail].

CASE ALLEGATIONS: PACS Group, through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. According to the PACS Group class action lawsuit, on or about April 11, 2024, PACS Group conducted its IPO, issuing approximately 21.4 million shares of common stock to the public at the offering price of $21.00 per share for net proceeds of approximately $450 million to PACS Group.

The PACS Group class action lawsuit alleges that defendants throughout the Class Period and in the IPO's offering documents made false and/or misleading statements and/or failed to disclose that: (i) PACS Group engaged in a "scheme" to submit false Medicare claims which "drove more than 100% of PACS' operating and net income from 2020-2023"; (ii) PACS Group engaged in a "scheme" to bill "thousands of unnecessary respiratory and sensory integration therapies to Medicare"; and (iii) PACS Group engaged in a scheme to falsify documentation related to licensure and staffing.